FTC stats show pharma backing off pay-for-delay deals after SCOTUS ruling

Tracy Staton

For years, the Federal Trade Commission lamented the ever-growing number of pay-for-delay patent settlements–three in 2005, 14 in 2007, up to a record 40 in 2012–and vowed to turn the tide. Now, it looks as if that's happening.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS